scispace - formally typeset
Y

Yousef Najajreh

Researcher at Al-Quds University

Publications -  40
Citations -  1315

Yousef Najajreh is an academic researcher from Al-Quds University. The author has contributed to research in topics: ABL & Cisplatin. The author has an hindex of 16, co-authored 37 publications receiving 1239 citations. Previous affiliations of Yousef Najajreh include Max Planck Society & Hebrew University of Jerusalem.

Papers
More filters
Journal ArticleDOI

Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.

TL;DR: The ability of low-frequency ultrasound (LFUS) to release encapsulated drugs from sterically stabilized liposomes in a controlled manner was demonstrated and it is proposed that the mechanism of release is a transient introduction of porelike defects in the liposome membrane, which occurs only during exposure to LFUS, after which the membrane reseals.
Journal ArticleDOI

Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.

TL;DR: In this article, the authors report on the interactions of cisplatin and transplatin with two model proteins, ubiquitin (Ub) and horse heart myoglobin (Mb), and attempt to answer the question whether proteins that have methionine-Pt adducts can transfer the platinum to biological nucleophiles and particularly to DNA.
Journal ArticleDOI

Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines.

TL;DR: The results reported here suggest that combination of positively charged ligands with a trans-Pt(II)Cl(2) center may lead to the discovery of platinum complexes that are able to circumvent cisplatin resistance.
Journal ArticleDOI

Facile Preparation of Mono‐, Di‐ and Mixed‐Carboxylato Platinum(IV) Complexes for Versatile Anticancer Prodrug Design

TL;DR: Facile strategies were developed for the versatile functionalization of platinum(IV) axial sites, allowing for easy accessibility to unsymmetric mono- and mixed-carboxylato, as well as symmetric di-substituted platinum( IV) complexes.
Journal ArticleDOI

DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.

TL;DR: The results support the view that one strategy of how to activate the trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist of a chemical modification of the ineffective transplatin that results in an increased stability of its intrastrand cross-links in double-helical DNA and/or in a increased efficiency to form interstrand cross- links.